Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, August 2007, p. 1050-1052, Vol. 14, No. 8
1071-412X/07/$08.00+0 doi:10.1128/CVI.00465-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Pediatrics,1 Division of Infectious Diseases, Department of Internal Medicine,2 Department of Laboratory Medicine, College of Medicine,3 Institute of Emerging Infectious Diseases, Korea University, Seoul, Korea4
Received 6 December 2006/ Returned for modification 13 March 2007/ Accepted 4 June 2007
|
|
|---|
|
|
|---|
Recently developed rapid influenza tests have had a positive impact on medical management by decreasing the need for ancillary tests and the use of antibiotics in children evaluated for an influenza-like illness in an emergency department (4, 12). Furthermore, they have increasingly become a useful tool for the surveillance of influenza activity (7, 13, 16).
Several rapid influenza antigen detection kits using enzyme, optical, or chromatographic immunoassays provide a result in 15 to 30 min, with reported sensitivities ranging from 62% to 85% and specificities ranging from 79.5% to 99% compared to viral cultures (1, 14).
A newly developed SD Bioline rapid influenza test (Standard Diagnostics, Inc., Suwon, Korea) is a lateral-flow immunoassay that uses influenza virus-specific monoclonal antibodies on a strip for the qualitative detection of influenza A and B virus antigens, separately. However, the performance of the test has not been determined to date. In this study, we compared the performance of the SD Bioline test with that of the QuickVue test (Quidel Corp., San Diego, CA), a nontyping lateral-flow immunoassay (3) which is currently the only rapid influenza test available in Korea, and further evaluated its clinical usefulness during the influenza season.
The study population was comprised of 295 Korean children and adults who were admitted to or visited the outpatient clinics at Korea University Anam Hospital with symptoms of acute respiratory tract illness during the 2005-to-2006 influenza season. Demographic and clinical data were collected using case report forms. Written informed consent to participate in the study was obtained from patients or their parents. The study protocol was approved by the hospital ethics committee (approval no. AN0560).
Three anterior nasal or throat swab specimens per adult patient were collected. One swab, for virus culture, was transferred in standard refrigerated HH medium (Hanks' balanced salt solution with 0.88% sodium bicarbonate, 0.2% bovine serum albumin [Sigma], 30 mM HEPES buffer, and 50 µg/ml gentamicin [9]), and the other two swabs were used for rapid influenza virus antigen testing. Nasopharyngeal aspirates and two throat swabs collected from each pediatric patient were used for virus culture and the influenza virus antigen tests, respectively. The specimen for culture was immediately placed in 2 ml of HH medium after the collection, transported to the virus laboratory on ice, and kept at –20°C until the culture was performed. Virus culture was performed using the cryopreserved R-Mix cultures (Diagnostic Hybrids, Inc., Athens, OH), as previously described (2, 8).
The QuickVue and SD Bioline tests were run in parallel. Four physicians (two pediatric and two infectious disease doctors) performed the tests, as described in the package inserts, at bedside or at the outpatient clinic throughout the study period. Briefly, both tests involved the extraction of influenza virus antigens from the patients' specimens. Each swab specimen was placed in a tube containing an extraction agent provided in each test kit. After the disruption of the viral particles, a test strip from each test kit was placed in the extraction tube and allowed to react with the influenza virus-specific monoclonal antibodies for 10 to 30 min. In the SD Bioline test, a pink-to-purple test line in the A or B region with the presence of a purple control line indicates a positive result for influenza virus A or B, respectively. With the QuickVue test, a pink-to-red test line in the presence of a blue control line indicates a positive result (3).
Data are represented as medians (ranges), unless otherwise indicated. The variables or frequencies were compared between the two groups using the Student t test or the chi-square test. Viral cultures positive for influenza virus A or B were considered true positives. All data analyses were performed using SPSS version 12.0 (SPSS, Inc., Chicago, IL).
The clinical characteristics of the study population are shown in Table 1. Among the 295 patients tested, overall detection rates for the virus culture, the QuickVue test, and the SD Bioline test were 25.4%, 15.9%, and 17.6%, respectively. Although the sensitivities and the specificities of the SD Bioline test were somewhat higher than those of the QuickVue test, none of these differences was significant (Table 2). Both tests were simple and easy to perform at bedside, but the SD Bioline test showed somewhat slow color development compared to the QuickVue test.
|
View this table: [in a new window] |
TABLE 1. Characteristics of the study population
|
|
View this table: [in a new window] |
TABLE 2. Performance of two rapid tests for the detection of influenza viruses
|
![]() View larger version (34K): [in a new window] |
FIG. 1. Detection of influenza viruses by culture and by the SD Bioline rapid antigen test in conjunction with an epidemic curve with two peaks of influenza activity based on the report from the KISS for the 2005-to-2006 season., influenza A reported by the KISS; , influenza B reported by the KISS; , influenza A virus detected by culture; , influenza B virus detected by culture; —, influenza A virus detected by the SD Bioline test; ----, influenza B virus detected by the SD Bioline test.
|
In conclusion, the SD Bioline rapid influenza test is useful for detecting influenza virus type A and type B. Within the recognized limitations, it might be a part of influenza surveillance programs for the influenza season.
This study was financially supported in part by Standard Diagnostics, Inc., Suwon, Korea, and in part by City of Seoul grant no. 10920.
Published ahead of print on 13 June 2007. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»